HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

WYE-687

an mTOR inhibitor; structure in first source

Networked: 2 relevant articles (0 outcomes, 0 trials/studies)

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Pyrazoles: 61
      - WYE-687: 2
  - Pyrimidines: 510
    - WYE-687: 2

Experts

1.	Chen, Xinfeng: 1 article (01/2017)
2.	Gu, Dong-Hua: 1 article (01/2017)
3.	Mao, Jia-Hui: 1 article (01/2017)
4.	Pan, Xiao-Dong: 1 article (01/2017)
5.	Shan, Yuxi: 1 article (01/2017)
6.	Zheng, Bing: 1 article (01/2017)
7.	Zhu, Hua: 1 article (01/2017)
8.	Chen, Heng: 1 article (02/2016)
9.	Cheng, Feng: 1 article (02/2016)
10.	Jiang, Yuanqiang: 1 article (02/2016)

Related Diseases

1.	Neoplasms (Cancer) 01/01/2017 - "Significantly, oral administration of WYE-687 potently suppressed786-O tumor xenograft growth in nude mice. " 02/05/2016 - "In vivo, oral administration of WYE-687 potently inhibited U937 leukemic xenograft tumor growth in severe combined immunodeficient (SCID) mice, without causing significant toxicities. "
2.	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 02/05/2016 - "Preclinical evaluation of WYE-687, a mTOR kinase inhibitor, as a potential anti-acute myeloid leukemia agent."
3.	Renal Cell Carcinoma (Grawitz Tumor) 01/01/2017 - "Concurrent inhibition of mTORC1 and mTORC2 by WYE-687 inhibits renal cell carcinoma cell growth in vitro and in vivo."
4.	Hypoxia (Hypoxemia) 01/01/2017 - "At the molecular level, WYE-687 almost completely blocked mTORC1 (p-S6K1 and p-S6) and mTORC2 (p-Akt Ser 473) activation in both 786-Ocells and primary human RCC cells, where it downregulated both hypoxia-inducible factor (HIF)-1α and HIF-2α expression. "

Related Drugs and Biologics

1.	Phosphotransferases (Kinase)
2.	Mechanistic Target of Rapamycin Complex 2
3.	Mechanistic Target of Rapamycin Complex 1

Related Therapies and Procedures

1.	Oral Administration